CA Patent

CA3182179A1 — Novel crystalline form of remdesivir

Assigned to Apotex Inc · Expires 2021-12-16 · 4y expired

What this patent protects

The present invention provides a novel crystalline form of remdesivir, remdesivir Form APO-I, comprising remdesivir and dimethyl sulfoxide, compositions and processes for the preparation thereof, the use of this crystalline form in the treatment of a viral infection, and methods …

USPTO Abstract

The present invention provides a novel crystalline form of remdesivir, remdesivir Form APO-I, comprising remdesivir and dimethyl sulfoxide, compositions and processes for the preparation thereof, the use of this crystalline form in the treatment of a viral infection, and methods of treating viral infections using the same, and in particular, a viral infection caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).

Drugs covered by this patent

Patent Metadata

Patent number
CA3182179A1
Jurisdiction
CA
Classification
—
Expires
2021-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Apotex Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.